Arbutus receives regulatory clearance to initiate phase 1a/1b clinical trial of AB-729
Arbutus Biopharma announced it has received regulatory clearance to initiate a Phase 1a/1b clinical trial of AB-729, Arbutus’ subcutaneously-administered RNA interference agent. AB-729 employs a single RNAi trigger that has been shown in preclinical models to span all HBV transcripts. June 20, 2019